These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 27748184)

  • 1. 177Lu-DOTA-Bevacizumab: Radioimmunotherapy Agent for Melanoma.
    Camacho X; Calzada V; Fernandez M; Alonso O; Chammas R; Riva E; Gambini JP; Cabral P
    Curr Radiopharm; 2017; 10(1):21-28. PubMed ID: 27748184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [(99m)Tc(CO)(3)]-radiolabeled bevacizumab: in vitro and in vivo evaluation in a melanoma model.
    Camacho X; García MF; Calzada V; Fernández M; Chabalgoity JA; Moreno M; Barbosa de Aguiar R; Alonso O; Gambini JP; Chammas R; Cabral P
    Oncology; 2013; 84(4):200-9. PubMed ID: 23328435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of (177)Lu-CHX-A''-DTPA-Bevacizumab as a radioimmunotherapy agent targeting VEGF expressing cancers.
    Kameswaran M; Pandey U; Gamre N; Vimalnath KV; Sarma HD; Dash A
    Appl Radiat Isot; 2016 Aug; 114():196-201. PubMed ID: 27258216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of
    Kameswaran M; Sarma HD; Dash A
    Appl Radiat Isot; 2017 May; 123():109-113. PubMed ID: 28260607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiolanthanide-labeled monoclonal antibody CC49 for radioimmunotherapy of cancer: biological comparison of DOTA conjugates and 149Pm, 166Ho, and 177Lu.
    Mohsin H; Jia F; Sivaguru G; Hudson MJ; Shelton TD; Hoffman TJ; Cutler CS; Ketring AR; Athey PS; Simón J; Frank RK; Jurisson SS; Lewis MR
    Bioconjug Chem; 2006; 17(2):485-92. PubMed ID: 16536481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.
    Chauhan SC; Jain M; Moore ED; Wittel UA; Li J; Gwilt PR; Colcher D; Batra SK
    Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):264-73. PubMed ID: 15791435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advantage of lutetium-177 versus radioiodine immunoconjugate in targeted radionuclide therapy of b-cell tumors.
    Repetto-Llamazares A; Abbas N; Bruland ØS; Dahle J; Larsen RH
    Anticancer Res; 2014 Jul; 34(7):3263-9. PubMed ID: 24982330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of (177)Lu-DOTA-Dendrimer and Determination of Its Effect on Metal and Ion Levels in Tumor Tissue.
    Kovacs L; Tassano M; Cabrera M; Zamboni CB; Fernández M; Anjos RM; Cabral P
    Cancer Biother Radiopharm; 2015 Dec; 30(10):405-9. PubMed ID: 26625257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators.
    D'Huyvetter M; Aerts A; Xavier C; Vaneycken I; Devoogdt N; Gijs M; Impens N; Baatout S; Ponsard B; Muyldermans S; Caveliers V; Lahoutte T
    Contrast Media Mol Imaging; 2012; 7(2):254-64. PubMed ID: 22434639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetraspanin 8 (TSPAN 8) as a potential target for radio-immunotherapy of colorectal cancer.
    Maisonial-Besset A; Witkowski T; Navarro-Teulon I; Berthier-Vergnes O; Fois G; Zhu Y; Besse S; Bawa O; Briat A; Quintana M; Pichard A; Bonnet M; Rubinstein E; Pouget JP; Opolon P; Maigne L; Miot-Noirault E; Chezal JM; Boucheix C; Degoul F
    Oncotarget; 2017 Mar; 8(13):22034-22047. PubMed ID: 28423546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation of (99m)Tc carbonyl DTPA-bevacizumab and its bioevaluation in a melanoma model.
    Kameswaran M; Pandey U; Sarma HD; Samuel G
    Ann Nucl Med; 2014 Nov; 28(9):911-6. PubMed ID: 25038907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
    Yao Z; Zhang M; Axworthy DB; Wong KJ; Garmestani K; Park L; Park CW; Mallett RW; Theodore LJ; Yau EK; Waldmann TA; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
    Cancer Res; 2002 Oct; 62(20):5755-60. PubMed ID: 12384535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic efficacy of a 177Lu-labeled DOTA conjugated alpha-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model.
    Miao Y; Shelton T; Quinn TP
    Cancer Biother Radiopharm; 2007 Jun; 22(3):333-41. PubMed ID: 17651039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
    J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo evaluation of novel ligands for radioimmunotherapy.
    Chong HS; Milenic DE; Garmestani K; Brady ED; Arora H; Pfiester C; Brechbiel MW
    Nucl Med Biol; 2006 May; 33(4):459-67. PubMed ID: 16720237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer.
    Rasaneh S; Rajabi H; Babaei MH; Daha FJ
    Nucl Med Biol; 2010 Nov; 37(8):949-55. PubMed ID: 21055626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
    Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
    Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.